covid
Buscar en
Infectio
Toda la web
Inicio Infectio Tuberculosis pleural asociada con adalimumab, en un paciente con artritis reumat...
Journal Information
Vol. 14. Issue 1.
Pages 47-54 (March 2010)
Share
Share
Download PDF
More article options
Vol. 14. Issue 1.
Pages 47-54 (March 2010)
Open Access
Tuberculosis pleural asociada con adalimumab, en un paciente con artritis reumatoide
Pleural tuberculosis associated with adalimumab in a patient with rheumatoid arthritis
Visits
2118
Patricia Hidalgo1,
Corresponding author
hidalgop@javeriana.edu.co

Unidad de Neumología, Hospital Universitario San Ignacio. Carrera 7 N° 40-62, Bogotá, D.C., Colombia. Teléfono: (571) 594-6175
, Jorge Echeverri2, Juan Martín Gutiérrez3
1 Médica internista, neumóloga, Hospital Universitario San Ignacio y Pontificia Universidad Javeriana, Bogotá, D.C., Colombia
2 Médico internista, nefrólogo, Hospital Universitario San Ignacio y Pontificia Universidad Javeriana, Bogotá, D.C., Colombia
3 Médico internista, reumátologo, Hospital Universitario San Ignacio y Pontificia Universidad Javeriana, Bogotá, D.C., Colombia
This item has received

Under a Creative Commons license
Article information
Resumen

La tuberculosis constituye, en nuestro medio, una de las enfermedades infecciosas endémicas. Con el advenimiento de las nuevas terapias para el control de la artritis reumatoide, como los inhibidores del factor de necrosis tumoral, la incidencia de casos de reactivación ha aumentado notoriamente.

Se presenta el caso de una mujer de 42 años de edad, con disnea, dolor torácico, tos, derrame pleural con líquido pleural tipo exudado linfocítico, con deaminasa de adenosina (ADA) de 55 U-L e identificación de granuloma en la biopsia pleural. Se revisa la literatura y se hacen recomendaciones.

Palabras clave:
tuberculosis
antagonistas del factor de necrosis tumoral
Abstract

Tuberculosis (TB) represents one of the endemic infectious diseases in our population. The incidence of reactivate TB cases has grown notoriously with the onset of new therapeutic options for controlling rheumatoid arthritis (RA), such as tumor necrosis factor (TNF) inhibitors.

The case of a 42 year old woman is highlighted. Her condition is characterized by shortness of breath, chest pain, cough, pleural effusion, linfocitic exudate pleural fluid, ADA 55 U-L and granuloma in pleural biopsy.

A review of relevant literature and recommendations are presented.

Key words:
Tuberculosis
tumor necrosis factor antagonist
Full text is only aviable in PDF
Referencias
[1.]
J. Ferrer.
Pleural tuberculosis.
Eur Respir J, 10 (1997), pp. 942-947
[2.]
J. Bieber, A. Kavanaugh.
Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatment.
Rheum Dis Clin of North America, 30 (2004), pp. 257-270
[3.]
Ministerio de Protección Social. Viceministerio de Salud y Bienestar. Representante OPS/OMS Colombia I.E. Instituto Nacional de Salud. Plan estratégico “Colombia libre de tuberculosis 2010–2015 para la expansión y fortalecimiento de la estrategia alto a la TB”. 2009.
[4.]
J. Keane, S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, et al.
Tuberculosis associated with infliximab, a tumor necrosis factor-α neutralizing agent.
N Eng J Med, 345 (2001), pp. 1098-1104
[5.]
B. Bresnihan, G. Cunnane.
Infection complications associated with the use of biologic agents.
Rheum Dis Clin North Am, 29 (2003), pp. 185-202
[6.]
C. Dukes.
Infectious complications of treatment with biologic agents.
Curr Opin Rheumatol, 16 (2004), pp. 393-398
[7.]
J. Ferrer.
Tuberculous pleural effusion and tuberculous empyema.
Sem Resp Crit Care Med, 21 (2001), pp. 637-643
[8.]
S. Ehlers.
Role of tumor necrosis factor (TNF) in host defense against tuberculosis: implications for immunotherapies targeting TNF.
Ann Rheum Dis, 62 (2003), pp. ii37-ii42
[9.]
A. Rojas-Villárraga, C. Agudelo, R. Pineda, A. Porras, G. Matute, et al.
Tuberculosis en pacientes tratados con antagonistas del factor de necrosis tumoral alfa en un área endémica: ¿vale la pena el riesgo?.
Biomédica, 27 (2007), pp. 159-171
[10.]
F. Tubach, D. Salmon, P. Ravaud, Y. Allanore, P. Goupille, et al.
Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French research axed on tolerance of biotherapies registry.
Arthritis Rheum, 60 (2009), pp. 1884-1894
[11.]
Scheldon K. Adalimumab for use in the treatment of rheumatoid arthritis. Center for Biologics Evaluation and Research Office of Therapeutics Research and Review Division of Clinical Trial Design and Analysis Immunology and Infectious Diseases Branch CLINICAL REVIEW Abbott, Biologic Licensing Application STN 125057?. Fecha de consulta: 2009. Disponible en: www.fda.gov.
[12.]
S. Chapman, R. Davies.
Pleural diseases. The management of pleural space infections.
[13.]
R. Light.
Pleural effusion.
N Engl J Med, 346 (2002), pp. 1971-1977
[14.]
R. Handa, R. Misra, V.P. Chaturvedi, P.K. Pispati, U.R.K. Rao.
Guidelines for tuberculosis prophylaxis during anti-tumour necrosis factor-treatment: Indian Rheumatology Association.
J Rheumatol, 9 (2006), pp. 181-183
[15.]
BTS recommendations for assessing risk and for managing M. tuberculosis infection, disease in patients due to start anti-TNF-alfa treatment.
Thorax, 60 (2005), pp. 800-805
[16.]
S. Munsiff, D. Nilsen, F. Dworkin.
Guidelines for testing and treatment of latent tuberculosis infection.
Department of Health and Mental Hygiene, Bureau of Tuberculosis Control, (2005),
[17.]
W. Rom, S. Garay.
Tuberculosis.
Second edition, Lippincott Williams & Wilkins, (2004),
[18.]
J.G. Montoya.
TB and transplants. Abstracts. First International Congress on Mycobacteria: A challenge for the 21st century.
Stanford University Medical Center, (2008),
[19.]
J.J. Blanco, A. Perez, J. Pego, M. Núñez, E. Temes, G. Guerra.
Tuberculosis pulmonar en relación con adalimumab: estudio de 3 casos.
Arch Bronconeumol, (2009),
Copyright © 2010. Asociación Colombiana de Infectología (ACIN)
Download PDF
Article options